| ID Source | ID |
|---|---|
| PubMed CID | 715715 |
| CHEMBL ID | 75913 |
| CHEMBL ID | 1321637 |
| CHEBI ID | 124646 |
| Synonym |
|---|
| CHEMBL75913 |
| n-[(5z)-4-chloro-5h-1,2,3-dithiazol-5-ylidene]-3,4,5-trimethoxyaniline |
| smr000025034 |
| MLS000090424 , |
| MLS-0053966.0001 |
| CHEBI:124646 |
| 4-chloro-n-(3,4,5-trimethoxyphenyl)dithiazol-5-imine |
| MLS002589851 |
| AKOS001729696 |
| STK774014 |
| HMS2274C08 |
| CHEMBL1321637 |
| (4-chlorodithiazol-5-ylidene)-(3,4,5-trimethoxyphenyl)amine |
| 4-chloranyl-n-(3,4,5-trimethoxyphenyl)-1,2,3-dithiazol-5-imine |
| 4-chloro-n-(3,4,5-trimethoxyphenyl)-5-dithiazolimine |
| bdbm33051 |
| cid_715715 |
| sr-01000103995 |
| SR-01000103995-1 |
| (5z)-4-chloro-n-(3,4,5-trimethoxyphenyl)-5h-1,2,3-dithiazol-5-imine |
| Q27214907 |
| Class | Description |
|---|---|
| substituted aniline | |
| methoxybenzenes | Any aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 63.0957 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 19.9054 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 4.2871 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 4.2871 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 4.4668 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 17.7828 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 11.2202 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 15.1014 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 3.1623 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| WRN | Homo sapiens (human) | Potency | 56.2341 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 14.1254 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 2.9286 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 22.5358 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 56.2341 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 2.8184 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 4.7748 | 0.2239 | 11.2451 | 35.4813 | AID624173; AID720569; AID720584 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 19.9526 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 28.1838 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.1220 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 25.1189 | 1.0000 | 12.2326 | 31.6228 | AID1452 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 2.2387 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 4.4668 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| fructose-bisphosphate aldolase A | Oryctolagus cuniculus (rabbit) | Potency | 31.6228 | 0.8913 | 16.5762 | 39.8107 | AID2794 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 25.1189 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 0.9466 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 3.9811 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 25.6651 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 18.3564 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 6.8168 | 0.2512 | 15.8432 | 39.8107 | AID504327; AID588347 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 25.1189 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 25.1189 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 2.8184 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 25.1189 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 5.6234 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 33.8078 | 0.0601 | 10.7453 | 37.9330 | AID485367 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| MPI protein | Homo sapiens (human) | IC50 (µMol) | 3.8335 | 0.1900 | 13.8256 | 50.1000 | AID1209; AID1535 |
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | IC50 (µMol) | 34.5000 | 0.8890 | 21.0286 | 71.5000 | AID504765; AID540252; AID540269 |
| phosphomannomutase 2 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.6720 | 34.7838 | 97.3000 | AID1655 |
| glucose-6-phosphate 1-dehydrogenase isoform b | Homo sapiens (human) | IC50 (µMol) | 69.4000 | 8.8700 | 12.8518 | 17.8000 | AID504792 |
| low molecular weight phosphotyrosine protein phosphatase isoform c | Homo sapiens (human) | IC50 (µMol) | 80.0000 | 4.9700 | 11.2567 | 19.6000 | AID652005 |
| eukaryotic translation initiation factor 4 gamma 1 isoform 4 | Homo sapiens (human) | IC50 (µMol) | 20.4256 | 1.1500 | 12.6200 | 25.6529 | AID855 |
| eukaryotic translation initiation factor 4E isoform 1 | Mus musculus (house mouse) | IC50 (µMol) | 20.4256 | 1.1500 | 12.6200 | 25.6529 | AID855 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 (µMol) | 7.2000 | 0.2700 | 26.3638 | 100.0000 | AID504719 |
| DNA dC->dU-editing enzyme APOBEC-3A isoform a | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 1.4800 | 14.5267 | 61.2000 | AID504722 |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 10.8000 | 0.0042 | 7.4680 | 21.1000 | AID2073 |
| Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) | IC50 (µMol) | 80.0000 | 2.8600 | 9.6336 | 17.2000 | AID651700 |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 10.8000 | 0.0003 | 7.3294 | 21.1000 | AID2073 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| bcl-2-related protein A1 isoform 1 | Homo sapiens (human) | EC50 (µMol) | 3.6300 | 1.2300 | 3.1550 | 6.5300 | AID1320 |
| hexokinase HKDC1 | Homo sapiens (human) | EC50 (µMol) | 56.9000 | 0.2120 | 0.2120 | 0.2120 | AID504730 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||